DNA-Encoded Library Decision Makers

| TARGET:

DNA-Encoded Library (DEL) Industry Scientists

| MARKET:

EU, US, other geographies possible

60-Minute Telephone/ Web IDIs 90-Minute Telephone/Web IDIs

| METHODOLOGY:

SPECS:

DEL Industry Scientists Pharmaceutical or biotech company employee Director level or above

Works in research and development in the early stages of drug discovery

- Must have insight into decisions around hit generation
- Must have insight into the use of DNA-encoded libraries
 - Nice to have insight into other early-stage processes (hit-to-lead, target validation, high-throughput screening, virtual high-throughput screening, fragment-based drug discovery)

European CRO Industry Experts

Works at contract research organization providing early-stage drug discovery services (hit-to-lead, target validation, hit generation, including DEL, high-throughput screening, virtual high-throughput screening, fragment-based drug discovery)

- Sample companies: Bicoll, Asclepia, Medchem Solutions, X-Chem, WuXi, HitGen
- Director level or above
- Works in business development or has insight into CRO business development

SAMPLE PROFILES:

- Chief Science Officer at RubrYc Therapeutics, Inc
- SVP, Drug Discovery at ZebiAl Therapeutics
- Director Discovery Process Research, Regional Head EMEA at The Janssen Pharmaceutical Companies of Johnson & Johnson
- Director, Hit Generation Science at Cygnal Therapeutics
- Head of Hit Discovery at AstraZeneca
- Senior Director, Business Development at WuHi AppTec company
- Chief Operating Officer & Head of Strategy at X-Chem, Inc

Contact us 49 W 38th St, New York, NY 10018

US (+1) 888-229-6664 | UK (+44) 020-8068-7070 info@InnovateMR.com

Locations

Los Angeles | New York | London | New Delhi | Toronto | Ahmedabad | Belgrade